Vesugen

What is it?

Vesugen is a Khavinson tripeptide (Lys-Glu-Asp / KED) targeting vascular endothelium — claimed to modulate gene expression for angiogenesis, endothelial repair, and vascular tone. It’s part of the vascular/cardiovascular corner of the Khavinson short-peptide bioregulator family, alongside Cardiogen. No structured study list existed on the source directory at capture time (2026-06-07), but a later verification pass (2026-06-22) surfaced real primary literature — see below.

What does it do in my body?

Claimed mechanism: like the rest of the Khavinson family, Vesugen is proposed to cross cell and nuclear membranes, bind DNA, and modulate transcription in a tissue-specific way — here, in vascular endothelial cells, promoting angiogenesis and endothelial repair.

How can it help me?

• Where the science stands: Directory listed “Anecdotal” (0 studies) at capture time; two primary papers since surfaced — one (mouse Alzheimer’s model), one

The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.

Is it dangerous? What are the side effects?

No serious AEs are documented for Vesugen specifically. The family-wide reported profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle.

The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space, and Vesugen’s thin published record makes it an easier target for mislabeling since there’s little independent literature to check a seller’s claims against. Third-party COA verification matters more here than for almost any other peptide class.

Regulatory status: Vesugen is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance. Unlike Thymalin, Vesugen holds no clinical-use approval anywhere.

Part 1 — How to reconstitute it

What's used: bacteriostatic water (sterile, preserved water the powder is mixed with) and a separate, larger reconstitution syringe used only for mixing — not the small syringe used for administration.

The exact bacteriostatic-water volume and resulting concentration for Vesugen are covered in the dosing notes and the deeper-science view. The right volume depends on the vial size.

How it's mixed

• The vial is tilted and the bacteriostatic water is added slowly down the inside glass wall — not squirted straight onto the powder.
• It is swirled gently to dissolve. It is never shaken — shaking can damage the peptide.
• The reconstituted vial is stored refrigerated and out of light.
• Reconstituted peptides are commonly used within a few weeks, inside the beyond-use window the source specifies — that window varies by peptide.

The free reconstitution calculator does the concentration math for any vial size and water volume, including the equivalent units on an insulin syringe.

Part 2 — Typical dosing

Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.

Administration as reported. Reported practice is subcutaneous administration (into the fat just under the skin) using a 0.3 mL U-100 insulin syringe, with sites rotated.

Educational purposes only — this reflects what the Russian-school protocol convention and the peptide community actually use, stated plainly; it is not medical advice.

There is no Western-validated dosing protocol for Vesugen in humans (the only human data is an observational cohort study, not a dose-finding trial). What exists is the Khavinson-school cycle pattern shared across the family:

• Cycle structure: a short course — typically 10–20 consecutive days — followed by a long rest, repeated 2–3 times per year.
• Dose: as a synthetic short tripeptide, community subcutaneous dosing converges around ~100–200 mcg/day over the cycle; no Vesugen-specific human dose-finding data exists to confirm this. The Khavinson mouse study used 400 μg/kg IP daily — not directly convertible to a human SubQ protocol.
• Storage: lyophilized powder is stable cold; once reconstituted with bacteriostatic water, refrigerate and use within roughly 28 days.

Treat every number above as community/Russian-protocol convergence, not validated human dosing.

Turning milligrams into syringe units. On a U-100 syringe, 100 units = 1 mL, so 1 unit = 0.01 mL. At a concentration of C mg/mL, a dose of D mg = D ÷ C mL = (D ÷ C) × 100 units. Example: at 5 mg/mL, a 0.5 mg dose = 0.1 mL = 10 units. The exact units depend on the vial's mg and the water volume used.

What should I avoid combining — and what's synergistic?

Vesugen doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.

Where do people source this?